0000950170-23-061563.txt : 20231109 0000950170-23-061563.hdr.sgml : 20231109 20231109083009 ACCESSION NUMBER: 0000950170-23-061563 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, Inc. CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 231390207 BUSINESS ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 BUSINESS PHONE: 858-400-8470 MAIL ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FORMER COMPANY: FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980501 8-K 1 virx-20231109.htm 8-K 8-K
false0001061027Viracta Therapeutics, Inc.00010610272023-11-092023-11-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 09, 2023

 

 

VIRACTA THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-51531

94-3295878

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2533 S. Coast Hwy. 101, Suite 210

 

Cardiff, California

 

92007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 400-8470

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VIRX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2023, Viracta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and the press release attached hereto as Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

 

 

Exhibit

Number

Description

 

 

99.1

Press Release, dated November 9, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Viracta Therapeutics, Inc

 

 

 

 

Date:

November 9, 2023

By:

/s/ Daniel Chevallard

 

 

 

Daniel Chevallard
Chief Operating Officer and Chief Financial Officer

 

 EX-99.1 2 virx-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

 

 

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

 

Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma showing an overall response rate and complete response rate of 40%

 

Reported interim data from the Phase 1b/2 trial of Nana-val in advanced EBV+ solid tumors with confirmed partial responses at higher doses and no dose-limiting toxicities observed to date

 

SAN DIEGO, November 9, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the third quarter of 2023.

 

“During our recently held R&D Day, we provided multiple clinical and strategic updates, which further positioned Nana-val as a differentiated potential therapeutic option for patients with EBV-associated cancers,” said Mark Rothera, President and Chief Executive Officer of Viracta. “Preliminary results from the PTCL cohort of the NAVAL-1 trial demonstrated overall and complete response rates of 40%, which are consistent with results from our previous Phase 1b/2 study and exceeds the current standard of care for this patient population with high unmet medical need. We continue to believe that Nana-val is an ideal candidate for the accelerated approval pathway and we remain on track to complete enrollment of the PTCL Stage 2 cohort and engage with FDA in 2024.”

 

“We also reported interim data from the Phase 1b/2 trial of Nana-val in advanced EBV-positive solid tumors with partial responses confirmed at higher doses. Given there have been no dose-limiting toxicities observed to date, we plan to evaluate higher doses of Nana-val that incorporate a novel split daily dosing schedule and determine the recommended Phase 2 dose of Nana-val for our solid tumor program in 2024. We have a well-defined strategic path forward, and with the PTCL indication leading the way, we continue to explore opportunities to maximize the therapeutic potential of Nana-val across other indications.”

 

Clinical Trial Updates and Anticipated Milestones

 

Pivotal NAVAL-1 study of Nana-val in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma

•
As of the data cutoff date of June 30, 2023, initial results from the first five patients with R/R EBV+ peripheral T-cell lymphoma (PTCL) treated with Nana-val showed an overall response rate (ORR) and complete response rate (CRR) of 40%.
•
Completion of enrollment into the nanatinostat monotherapy arm (n=10) and Nana-val combination arm (n=10) of the NAVAL-1 R/R EBV+ PTCL cohort is anticipated by year-end 2023.
•
Amended the NAVAL-1 protocol to additionally enroll second-line patients across all cohorts, including diffuse large B-cell lymphoma (DLBCL) and post-transplant lymphoproliferative disorder (PTLD).

Page | 1

Exhibit 99.1

 

•
Anticipated 2024 milestones:
o
Stage 1 data from both arms of the R/R EBV+ PTCL cohort (in patients treated with nanatinostat with or without valganciclovir).
o
Completion of enrollment into Stage 2 of the Nana-val R/R EBV+ PTCL cohort (n=21).
o
U.S. Food and Drug Administration (FDA) meeting to discuss additional requirements for accelerated approval for the treatment of patients with R/R EBV+ PTCL.
o
Stage 2 data from the Nana-val R/R EBV+ PTCL cohort.

 

Additional response and durability assessments from the Phase 1b/2 trial (Study 201) of Nana-val in patients with R/R EBV+ lymphoma as of the May 4, 2023 data cutoff date

•
For patients with R/R EBV+ PTCL, median duration of response (DoR) was 17.3 months with an ORR/CRR of 50%/38% (n=8).
•
For patients with R/R EBV+ DLBCL, median DoR has not yet been reached, with three patients remaining in response with DoRs of 11.1 months (complete response [CR]), 36.8 months (partial response [PR]), and 41.9 months (CR), with an ORR/CRR of 67%/33% (n=9).
•
Expanded and extended safety data demonstrated Nana-val regimen was generally well-tolerated with the potential to combine with other chemo/immunotherapies.

 

New interim clinical data in Phase 1b/2 study of Nana-val in patients with advanced EBV+ solid tumors (Study 301) highlight the opportunity to dose escalate further with a novel dosing regimen to potentially drive additional responses in this patient population. This approach is supported by growing preclinical data.

•
Enrollment completed through the fifth dose level without any dose-limiting toxicities reported.
•
Best responses to date included two confirmed PRs at the higher dose levels and five stable diseases in 17 patients with recurrent or metastatic (R/M) EBV+ nasopharyngeal carcinoma (NPC).
•
In a preclinical murine xenograft model, split daily dosing (SDD) of Nana-val had superior anti-tumor activity than intermittent (four days on/three days off) once-daily dosing, which supports the evaluation of an SDD regimen in patients with advanced EBV+ solid tumors.
•
Anticipated 2024 milestones:
o
Additional dose levels are planned with Nana-val on an SDD schedule to select a recommended Phase 2 dose (RP2D); enrollment anticipated to be resumed by year-end 2023.
o
Initiation of the clinical trial’s randomized Phase 2 expansion cohort designed to further evaluate Nana-val at the RP2D.

 

Business Update

 

•
On October 4, 2023, Viracta hosted an R&D Day highlighting Nana-val clinical programs in EBV-associated cancers. The R&D Day featured key opinion leaders, Pierluigi Porcu, M.D. and Robert A. Baiocchi, M.D., Ph.D.
o
Drs. Porcu and Baiocchi discussed the current treatment landscape of EBV+ lymphomas and Nana-val’s opportunity to address the unmet medical needs of this unique cancer segment.
o
Members of Viracta’s senior management team provided updates on the Nana-val clinical development programs in patients with R/R EBV+ lymphoma and in patients with R/M EBV+ NPC.
o
A replay of the presentation is available here

Page | 2

Exhibit 99.1

 

 

Third Quarter 2023 Financial Results

 

•
Cash position – Cash, cash equivalents, and short-term investments totaled approximately $63.0 million as of September 30, 2023, which is anticipated to fund Viracta’s operations through late 2024 and does not include any adjustments that may arise from uncertainties related to our ability to continue as a going concern. This also excludes any additional borrowing under a $50.0 million credit facility, of which $25.0 million remains available, at the Company’s request and subject to the discretion of the lenders.
•
Research and development expenses – Research and development (R&D) expenses were approximately $8.2 million and $24.0 million for the three and nine months ended September 30, 2023, respectively, compared to approximately $7.1 million and $19.6 million for the same periods in 2022. This increase in R&D expenses was primarily driven by increases in costs incurred to support the advancement and expansion of our clinical development programs, including incremental costs to support NAVAL-1, our pivotal study of Nana-val in patients with R/R EBV+ lymphoma, and the initiation of our Phase 1b/2 study of Nana-val for the treatment of patients with EBV+ solid tumors, as well as an increase in personnel-related costs.
•
General and administrative expenses – General and administrative (G&A) expenses were approximately $4.3 million and $13.2 million for the three and nine months ended September 30, 2023, respectively, compared to $10.9 million and $19.5 million for the same periods in 2022. The decrease in G&A expenses was largely due to a non-recurring share-based compensation expense of $5.6 million associated with modifications to certain equity awards in conjunction with a separation agreement for the former Chief Executive Officer in September 2022. In addition, $0.8 million in one-time severance-related charges were recorded in the three and nine months ended September 30, 2022 in accordance with the terms of the separation agreement.
•
Net loss – Net loss was approximately $12.6 million, or $0.33 per share, (basic and diluted) for the quarter ended September 30, 2023, compared to a net loss of $17.7 million, or $0.47 per share, (basic and diluted) for the same period in 2022. Net loss was approximately $37.3 million, or $0.97 per share, (basic and diluted) for the nine months ended September 30, 2023, compared to a net loss of $38.9 million, or $1.03 per share, (basic and diluted) for the same period in 2022.

 

About NAVAL-1

NAVAL-1 (NCT05011058) is a global, multicenter, clinical trial of Nana-val in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma. This trial employs a Simon two-stage design where, in Stage 1, participants are enrolled into one of three indication cohorts based on EBV+ lymphoma subtype. If a pre-specified antitumor activity threshold is reached within a lymphoma subtype in Stage 1 (n=10), then additional patients will be enrolled in Stage 2 for a total of 21 patients. EBV+ lymphoma subtypes demonstrating promising antitumor activity in Stage 2 may be further expanded following discussion with regulators to potentially support registration.

 

About the Phase 1b/2 Study of Nana-val in R/M EBV+ NPC and Other Advanced EBV+ Solid Tumors

This Phase 1b/2 trial (NCT05166577) is an open-label, multinational clinical trial evaluating Nana-val alone and in combination with pembrolizumab. The Phase 1b dose escalation part is designed to evaluate safety and to determine the Recommended Phase 2 Dose (RP2D) of Nana-val in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcinoma (NPC). In Phase 2, up to 60 patients with R/M EBV+ NPC will be randomized to receive Nana-val at the RP2D with or without pembrolizumab to further evaluate antitumor activity, safety and tolerability, pharmacokinetics, and

Page | 3

Exhibit 99.1

 

potential pharmacodynamic biomarkers. Additionally, patients with other advanced EBV+ solid tumors will be enrolled to receive Nana-val at the RP2D in a Phase 1b dose expansion cohort.

 

About Nana-val (Nanatinostat and Valganciclovir)

Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies. Nanatinostat is currently being investigated in combination with the antiviral agent valganciclovir as an all-oral combination therapy, Nana-val, in various subtypes of EBV-associated malignancies. Ongoing trials include a pivotal, global, multicenter, open-label Phase 2 basket trial in multiple subtypes of relapsed or refractory (R/R) EBV+ lymphoma (NAVAL-1) as well as a multinational Phase 1b/2 clinical trial in patients with recurrent or metastatic (R/M) EBV+ NPC and other EBV+ solid tumors.

 

About EBV-Associated Cancers

Approximately 90% of the world's adult population is infected with EBV. Infections are commonly asymptomatic or associated with mononucleosis. Following infection, the virus remains latent in a small subset of cells for the duration of the patient's life. Cells containing latent virus are increasingly susceptible to malignant transformation. Patients who are immunocompromised are at an increased risk of developing EBV-positive (EBV+) lymphomas. EBV is estimated to be associated with approximately 2% of the global cancer burden including lymphoma, nasopharyngeal carcinoma (NPC), and gastric cancer.

 

About Viracta Therapeutics, Inc.

Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV+ nasopharyngeal carcinoma (NPC) and other advanced EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.

 

For additional information, please visit www.viracta.com.

 

Forward-Looking Statements

This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the details, timeline and expected progress for Viracta's ongoing and anticipated clinical trials and updates regarding the same, the Company’s expectations related to the FDA submission process and timelines, expectations regarding our target patient populations, and expectations regarding our cash runway. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta's ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta's plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta's planned clinical trials; the timing of the availability of data from Viracta's clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta's plans to research,

Page | 4

Exhibit 99.1

 

develop, and commercialize its current and future product candidates; the clinical utility, potential benefits, and market acceptance of Viracta's product candidates; Viracta's ability to manufacture or supply nanatinostat, valganciclovir, and pembrolizumab for clinical testing; Viracta's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Viracta's competitors and its industry; the impact of government laws and regulations; Viracta's ability to protect its intellectual property position; and Viracta's estimates regarding its ability to fund ongoing operations to or beyond late 2024, future expenses, capital requirements, and need for additional financing in the future.

 

If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" and elsewhere in Viracta's reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at www.sec.gov.

 

The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

 

Investor Relations Contact:

Ashleigh Barreto

Head of Investor Relations & Corporate Communications

Viracta Therapeutics, Inc.

abarreto@viracta.com

 

SOURCE Viracta Therapeutics, Inc.

 

-- Financial tables attached –

 

Page | 5

Exhibit 99.1

 

Viracta Therapeutics, Inc.

 

Selected Balance Sheet Highlights

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

 

December 31,

 

 

 

2023

 

 

 

2022

 

 

 

(Unaudited)

 

 

 

 

 

Cash, cash equivalents and short-term investments

$

 

62,952

 

 

$

 

91,043

 

Total assets

$

 

66,437

 

 

$

 

95,991

 

Total liabilities

$

 

36,429

 

 

$

 

34,888

 

Stockholders' equity

$

 

30,008

 

 

$

 

61,103

 

 

 

Viracta Therapeutics, Inc.

 

Condensed Consolidated Statement of Operations and Comprehensive Loss

 

(in thousands except share and per share data)

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 $

 

8,158

 

 

 $

 

7,139

 

 

 $

 

23,962

 

 

 $

 

19,559

 

General and administrative

 

 

4,317

 

 

 

 

10,939

 

 

 

 

13,170

 

 

 

 

19,456

 

Total operating expenses

 

 

12,475

 

 

 

 

18,078

 

 

 

 

37,132

 

 

 

 

39,015

 

Loss from operations

 

 

(12,475

)

 

 

 

(18,078

)

 

 

 

(37,132

)

 

 

 

(39,015

)

Total other income (expense)

 

 

(125

)

 

 

 

335

 

 

 

 

(161

)

 

 

 

144

 

Net loss

 

 

(12,600

)

 

 

 

(17,743

)

 

 

 

(37,293

)

 

 

 

(38,871

)

Unrealized gain (loss) on short-term investments

 

 

50

 

 

 

 

(199

)

 

 

 

113

 

 

 

 

(199

)

Comprehensive loss

 

 

(12,550

)

 

 

 

(17,942

)

 

 

 

(37,180

)

 

 

 

(39,070

)

Net loss per share, basic and diluted

 $

 

(0.33

)

 

 $

 

(0.47

)

 

 $

 

(0.97

)

 

 $

 

(1.03

)

Weighted-average common shares
outstanding, basic and diluted

 

 

38,683,858

 

 

 

 

37,705,517

 

 

 

 

38,568,515

 

 

 

 

37,614,166

 

 

Page | 6

 EX-101.PRE 3 virx-20231109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 virx-20231109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 5 virx-20231109.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity Registrant Name Viracta Therapeutics, Inc.
Entity Central Index Key 0001061027
Entity Emerging Growth Company false
Securities Act File Number 000-51531
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3295878
Entity Address, Address Line One 2533 S. Coast Hwy. 101, Suite 210
Entity Address, City or Town Cardiff
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92007
City Area Code (858)
Local Phone Number 400-8470
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol VIRX
Security Exchange Name NASDAQ
XML 7 virx-20231109_htm.xml IDEA: XBRL DOCUMENT 0001061027 2023-11-09 2023-11-09 false 0001061027 Viracta Therapeutics, Inc. 8-K 2023-11-09 DE 000-51531 94-3295878 2533 S. Coast Hwy. 101, Suite 210 Cardiff CA 92007 (858) 400-8470 false false false false Common Stock, par value $0.0001 per share VIRX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " ##0VE799!YDAD! M #/ P $P @ ')$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 "0 ) #X" 3% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports virx-20231109.htm virx-20231109.xsd virx-20231109_lab.xml virx-20231109_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "virx-20231109.htm": { "nsprefix": "virx", "nsuri": "http://viracta.com/20231109", "dts": { "inline": { "local": [ "virx-20231109.htm" ] }, "schema": { "local": [ "virx-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "virx-20231109_lab.xml" ] }, "presentationLink": { "local": [ "virx-20231109_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_f04ee532-1f5a-4f7a-b0a1-c7c5076cf3b8", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "virx-20231109.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f04ee532-1f5a-4f7a-b0a1-c7c5076cf3b8", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "virx-20231109.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://viracta.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000950170-23-061563-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-061563-xbrl.zip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